CIK 0002012593 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Rapport Therapeutics, Inc.
Sign in to watch- Ticker
- RAPP
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 880724208
- Phone
- 857-321-8020
- Business address
- 99 HIGH STREET, SUITE 2100, BOSTON, MA, 02110
- Former names
- Rapport Therapeutics, Inc.
- Open-market buys, last 90 days
- $22,023,904
- in 7 filings
- Open-market sales, last 90 days
- $4,490,340
- in 8 filings, $4.5M under 10b5-1 plans
Net +$17,533,565. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-06-06 | Galer Bradley S. Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +123,818 | 123,818 | ||
| 2024-06-06 | Gault Cheryl Chief Operations Officer | Grant or award · Stock Option (Right to Buy) | +88,442 | 88,442 | ||
| 2024-06-06 | Bredt David Chief Scientific Officer | Grant or award · Stock Option (Right to Buy) | +28,302 | 28,302 | ||
| 2024-06-06 | Yeleswaram Krishnaswamy Chief Development Officer | Grant or award · Stock Option (Right to Buy) | +84,904 | 84,904 | ||
| 2024-06-06 | Ceesay Abraham Chief Executive Officer | Grant or award · Stock Option (Right to Buy) | +530,647 | 530,647 | ||
| 2024-06-06 | Ignelzi Troy A. Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +81,366 | 81,366 |
Page 10 of 10 · 186 trades